Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations

被引：76

作者：

Yang, Wei ^{[1
]}

Raufi, Alexander ^{[1
]}

Klempner, Samuel J. ^{[2
]}

机构：

[1] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA

[2] Univ Calif Irvine, Div Hematol Oncol, Orange, CA 92668 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2014年 / 1846卷 / 01期

关键词：

Targeted therapy; Gastric; Cancer; Mutation; Proteomics; Sequencing; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; PHASE-III TRIAL; PROGNOSTIC-SIGNIFICANCE; FACTOR RECEPTOR; CLINICOPATHOLOGICAL SIGNIFICANCE; ESOPHAGEAL ADENOCARCINOMA; NEOADJUVANT CHEMOTHERAPY;

D O I：

10.1016/j.bbcan.2014.05.003

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Gastric cancer is currently the second leading cause of worldwide cancer mortality. Ongoing collaborative sequencing efforts have highlighted recurrent somatic genomic aberrations in gastric cancer, however, despite advances in characterizing the genomic landscape, there have been few advances in patient outcomes. Prognosis remains poor with a median overall survival of 12 months for advanced disease. The improved survival with trastuzumab, and more recently ramucirumab, underscore the promise of targeted and biologic therapies and the importance of molecular tumor characterization in gastric cancer. Here we review the most frequent actionable alterations in gastric cancer and highlight ongoing clinical investigations attempting to translate biologic understanding into improved clinical outcomes. (C) 2014 Elsevier B.V. All rights reserved.

引用

页码：232 / 237

页数：6

共 96 条

[1]

[Anonymous], 2014, J CLIN ONCOL S3, V32

[2] MET Signaling Pathway: A Rational Target for Cancer Therapy [J].